Thursday, April 28, 2011

InterMune leaves sale rumors unanswered

InterMune Inc. is not for sale — now stop asking.
That’s the takeaway from the Brisbane company’s (NASDAQ: ITMN) first-quarter recap conference call Thursday morning. But sources told Bloomberg and this week that the developer of the idiopathic pulmonary fibrosis drug Esbriet has been shopped around for a few weeks. Bloomberg said Goldman Sachs is managing the process.

No comments:

Post a Comment